Open an account

AC Immune SA

ACIU · NASDAQ

$2.49+$0.055 (+2.26%)TodayMarket closed ·
Prev close $2.44

About ACIU

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Employees
122
Headquarters
Lausanne, Vaud
Listed
Sep 23, 2016
Sector
Health Care
Industry
Biotechnology
Website
acimmune.com

ACIU key statistics

Market cap
253.42M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
213.21K
Volume
140.11K
Open price
$2.41
High today
$2.53
Low today
$2.40
52 Week high
$4.00
52 Week low
$2.10

AC Immune SA (ACIU) at a glance

As of Oct 20, 2026, AC Immune SA (ACIU) shares are priced at $2.49, giving the company a market cap of 253.42M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.40 and $2.53. The current price is 4.0% above the day's low and 1.4% below its high.

Volume so far is 140.11K shares, below the average of 213.21K shares a day.

Over the past year AC Immune SA has ranged from $2.10 to $4.00, and now sits 21% of the way up that range.

AC Immune SA met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.02 per share against an estimate of -$0.1136.

The average analyst price target is $9.27, 272.1% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $9.27
Low
$5.45
Now
$2.49
High
$12.60

ACIU earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 44.8% on average.

  1. Q3 FY24: reported $0.05 per share against an estimate of -$0.1997
  2. Q4 FY24: reported -$0.16 per share against an estimate of -$0.1911
  3. Q1 FY25: reported -$0.19 per share against an estimate of -$0.2091
  4. Q2 FY25: reported -$0.21 per share against an estimate of -$0.178
  5. Q3 FY25: reported -$0.16 per share against an estimate of -$0.195
  6. Q4 FY25: reported -$0.13 per share against an estimate of -$0.1717
  7. Q1 FY26: reported -$0.15 per share against an estimate of -$0.1551
  8. Q2 FY26: reported $0.02 per share against an estimate of -$0.1136

ACIU news

  • Vandana Singh

    AC Immune Says Investigational Parkinson’s Drug Shows 100% Antibody Response

  • Vandana Singh

    AC Immune Says Early Data from Anti-Inflammatory Drug Gives Wider Clinical Momentum for Pipeline

  • Press releaseGlobe Newswire

    AC Immune First Half 2026 Financial and Corporate Update

  • Press releaseGlobe Newswire

    AC Immune First Quarter 2026 Financial and Corporate Updates

  • Press releaseGlobe Newswire

    AC Immune Reports Full Year 2025 Financial Results and Provides a Corporate Update

  • Press releaseGlobe Newswire

    AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

  • 'FDA Clears First Blood Test Used In Diagnosing Alzheimer's Disease; New Test Provides Less Invasive Option, Reduces Reliance On Pet Scans And Increases Diagnosis Accessibility' - FDA

  • Avi Kapoor

    S&P 500 Moves Lower; US Crude Oil Inventories Increase

Similar companies

Companies in the same industry as AC Immune SA

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.